Loading...
Market
Which company will enter into a new partnership with Illumina for oncology diagnostics by the end of 2024?
3
Resolution / Starting Odds
Pfizer • 25%
Merck • 25%
Roche • 25%
Other • 25%
Official partnership announcements or press releases
Story
FDA Approves Illumina's TruSight Oncology Comprehensive for Bayer and Lilly Therapies
Aug 27, 2024, 02:01 PM
The U.S. Food and Drug Administration (FDA) has approved Illumina's TruSight Oncology Comprehensive assay, a cancer biomarker test designed to rapidly match patients to targeted therapies. This test includes two companion diagnostics and is specifically approved as a companion diagnostic (CDx) for kinase inhibitors from pharmaceutical companies Bayer and Lilly. The assay identifies patients with NTRK gene fusions who may benefit from Bayer's Vitrakvi (larotrectinib) and those with RET fusion-positive cancers who may benefit from Lilly's Retevmo (selpercatinib).
View original story
Similar markets
A cancer diagnostics company • 25%
A gene sequencing company • 25%
A biotech company unrelated to cancer diagnostics • 25%
No major acquisition • 25%
Roche • 25%
Novartis • 25%
Pfizer • 25%
Other • 25%
Illumina • 25%
Thermo Fisher Scientific • 25%
Pacific Biosciences • 25%
Other • 25%
Pfizer • 25%
Merck • 25%
Johnson & Johnson • 25%
Other • 25%
Mayo Clinic • 25%
Cleveland Clinic • 25%
Kaiser Permanente • 25%
Other • 25%
Yes • 50%
No • 50%
Pfizer • 25%
Roche • 25%
Novartis • 25%
Other • 25%
A major pharmaceutical company (e.g., Pfizer, Merck) • 25%
A major tech company (e.g., Google, Microsoft) • 25%
A major hospital network (e.g., Mayo Clinic) • 25%
Other • 25%
Pfizer • 25%
Johnson & Johnson • 25%
Novartis • 25%
Other • 25%
Illumina • 25%
Thermo Fisher • 25%
Roche • 25%
Other • 25%
Pfizer • 25%
Merck • 25%
Roche • 25%
Other • 25%